Electronic Acknowledgement Receipt				
EFS ID:	11639218			
Application Number:	10574302			
International Application Number:				
Confirmation Number:	7066			
Title of Invention:	Aerosol Formulation Comprising Formoterol in Suspension			
First Named Inventor/Applicant Name:	Rudi Mueller-Walz			
Customer Number:	30623			
Filer:	Muriel M. Liberto/Kimberly Jones			
Filer Authorized By:	Muriel M. Liberto			
Attorney Docket Number:	28069-623N01US			
Receipt Date:	16-DEC-2011			
Filing Date:	02-NOV-2006			
Time Stamp:	14:12:58			
Application Type:	U.S. National Stage under 35 USC 371			

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$1490
RAM confirmation Number	539
Deposit Account	500311
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
Request for Continued Examination (RCE)	28069_623N01US_RCE.pdf	68391	no	1	
		0ea5c75f9a40f902066f56c32595138c1760 6fa7			
Warnings:					
This is not a USP	TO supplied RCE SB30 form.				
Information:					
2 Amendment After Final	28069_623N01US_Response_t o_Final_Office_Action.pdf	291775	no	10	
		8e05cc4ba0609f91011bf640a93a01bcf200 250f			
Warnings:					
Information:					
3 Rule 130, 131 or 132 Affidavits	28069_623N01US_Declaration _under_37_CFR_1_132_with_E	109497	no	3	
		xhibit_A.pdf	17a0edcb1f14bd90502102d0479851f9b9b 2cf64		
Warnings:	·				
Information:					
4 Rule 130, 131 or 132 Affidavits	28069_623N01US_Declaration _under_37_CFR_1_132_pdf.pdf	91109	no	2	
		ef70715fc7a1a49bd34cdce4e60849a088a7 c68f			
Warnings:					
Information:	Ţ		ı ı		
5	Information Disclosure Statement (IDS) Form (SB08)	28069_623N01US_Modified_14 49pdf	111828	no	1
			80995ccd844782e15443d1cee93a4916667 66605		
Warnings:					
Information:					
This is not an US	SPTO supplied IDS fillable form				
6 Transmittal Letter	28069_623N01US_IDS_Letter pdf	90758	no	1	
		e48c91e1a0f554ee00e2e56bf4b738477619 f6aa			
Warnings:					
Information:					
7 Fee Worksheet (SB06)	fee-info.pdf	32374	no	2	
		b72222b3cc1849521e27f389d4cd07b7dbf b652b			
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.